De Vera, Dante E.

HRN: 27-22-96  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/28/2026
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
06/28/2026
07/05/2026
IVT
4.5g Now Then 2.25g IVT Q8
Q8
CAP HR
Checking Initial Appropriateness 
07/02/2026
CLINDAMYCIN 150MG/ML, 4ML (AMP)
07/02/2026
07/08/2026
IV
600mg
Q6
Cellulitis
Checking Initial Appropriateness 
07/04/2026
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
07/04/2026
07/11/2026
TOPICAL
1%
BID
Cellulitis
Checking Initial Appropriateness 
07/04/2026
MUPIROCIN 2%, 15G (TUBE)
07/04/2026
07/11/2026
TOPICAL
2%
BID
Cellulitis
Checking Initial Appropriateness 
07/09/2026
CLINDAMYCIN 300MG (CAP)
07/09/2026
07/16/2026
ORAL
500mg
Q 8
Infected Wound
Checking Initial Appropriateness 
07/14/2026
CLINDAMYCIN 300MG (CAP)
07/14/2026
07/21/2026
ORAL
300mg
Q 8 Hours
Cellulitis
Checking Final Appropriateness 
07/14/2026
MUPIROCIN 2%, 15G (TUBE)
07/14/2026
07/21/2026
TOPICAL
Apply Thinly
BID
Cellulitis
Checking Final Appropriateness 
07/14/2026
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
07/14/2026
07/21/2026
TOPICAL
Apply Thinly
BID
Cellulitis
Checking Final Appropriateness 
07/17/2026
CLINDAMYCIN 300MG (CAP)
07/17/2026
07/23/2026
PO
300mg
TID
Cellulitis
Checking Final Appropriateness 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: